Immune thrombocytopenia relapse post covid-19 vaccine in young male patient
| Autor: | Elrazi Ali, Mohamad A Yassin, Hana Qasim |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Spleen Case Report Infectious and parasitic diseases RC109-216 Immune system immune system diseases Internal medicine hemic and lymphatic diseases medicine Platelet Relapse Pfizer vaccine Dexamethasone biology business.industry SARS-CoV-2 Emergency department medicine.disease Thrombocytopenic purpura Pathophysiology Infectious Diseases medicine.anatomical_structure biology.protein ITP Antibody business medicine.drug |
| Zdroj: | IDCases, Vol 26, Iss, Pp e01344-(2021) IDCases |
| ISSN: | 2214-2509 |
| Popis: | Immune thrombocytopenic purpura (ITP) is a blood disorder in which antibodies coating platelets cause platelets destruction in the spleen with resultant low platelets count and an increased tendency for bleeding. Coronavirus disease 2019 (COVID-19) is an illness caused by SARS-COV2; it was first identified in December/2019; though it mainly affects the respiratory system, multisystemic complications are identified. Several ITP cases post mRNA SARS-CoV-2 vaccines were reported, and different pathophysiology theories about the underlying pathophysiology were discussed, but only a few ITP relapse cases have been reported so far. We present a 28-year-old Asian male, a known patient of ITP and in partial remission for eighteen months, who presented to the emergency department with ITP relapse (platelets count of 1 × 10^3 /µL), four days after receiving the second dose of Pfizer SARS-CoV-2 vaccine, which required treatment with intravenous immunoglobulins and dexamethasone. We further discuss the preferred approach in ITP patients who are willing to receive the COVID-19 vaccine. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|